Complement in monoclonal antibody therapy of cancer - PubMed (original) (raw)

Review

Complement in monoclonal antibody therapy of cancer

Laura M Rogers et al. Immunol Res. 2014 Aug.

Abstract

Monoclonal antibodies (mAb) have been used as targeted treatments against cancer for more than a decade, with mixed results. Research is needed to understand mAb mechanisms of action with the goal of improving the efficacy of currently used mAbs and guiding the design of novel mAbs. While some mAb-induced tumor cell killing is a result of direct effects on tumor cell signaling, mAb opsonization of tumor cells also triggers activation of immune responses due to complement activation and engagement of antibody receptors on immune effector cells. In fact, complement has been shown to play an important role in modulating the anti-tumor activity of many mAb through complement-dependent cytotoxicity, antibody-dependent cytotoxicity, and through indirect effects by modulating the tumor microenvironment. Complement activity can have both agonistic and antagonistic effects on these processes. How the balance of such effects impacts on the clinical efficacy of mAb therapy remains unclear. In this review, we discuss the mAbs currently approved for cancer treatment and examine how complement can impact their efficacy with a focus on how this information might be used to improve the clinical efficacy of mAb treatment.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Complement and mAb Efficacy

Antibody therapy activates complement through the classical pathway, with subsequent amplification through the alternative pathway, and complement regulators (red text) act on many levels. The components that impact mAb anti-tumor activity (circled in blue) have complex effects, and a summary is given below. C1active: Promotes mAb induced CDC [21, 22, 24]. C3: Inhibits T cell proliferation through CR1 signaling [63]. C3b: Prevents ADCC by disrupting mAb interaction with FcγR [49]. C3a and C5a: Promotes CDC, but Induces inflammatory (and possibly tumor-permissive) microenvironment [–62, 64]. DAF (CD55), MCP (CD46), and CD59: Prevent CDC, but may also directly block ADCC [–, , –47].

References

    1. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998;16(8):2825–33. - PubMed
    1. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;341(6151):1192–8. doi: 10.1126/science.1241145. - DOI - PubMed
    1. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17(9):2639–48. - PubMed
    1. Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Seminars in oncology. 2003;30(4):424–33. - PubMed
    1. Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer biology & therapy. 2011;11(9):777–92. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources